Hepatitis C - Human Genome Sciences, Inc. (HGSI) Reports Interim Results Of Phase 2 Clinical Trial Of Albuferon(TM) in Combi

Human Genome Sciences, Inc. (HGSI) Reports Interim Results Of Phase 2 Clinical Trial Of Albuferon(TM) in Combi
BioSpace - combination with ribavirin (RBV) in patients with chronic hepatitis C who failed to respond to previous to Prior Interferon Therapy for Chronic Hepatitis C.'(1) The trial is

Schering-Plough Corporation (SGP)'s Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity As Mono
BioSpace - representing an area of great unmet medical need. Chronic hepatitis C affects more than 10 million people in major world

Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monotherapy and in Com
Canada NewsWire - Results Reported at American Association for the Study of Liver Diseases (AASLD) Meeting Large Phase II Combination Study Under Way SAN FRANCISCO, Nov. representing an area of great unmetmedical need. Chronic hepatitis C affects more than 10 million people inmajor world